Associated tags: Trichloroethylene, Therapy, Cancer, EGFR, TCE, PSMA, CD28, Pharmacokinetics, Patient, Cluster, Half-life, PD-L1, Cytokine release syndrome, Immune system, Research, Pharmaceutical, Biotechnology, Health, Oncology, Science, Pharmaceutical industry, Hematological Cancer Research Investment and Education Act
Locations: NEW YORK, WALL STREET, UNITED STATES, NORTH AMERICA, CALIFORNIA, TD, ILLINOIS, CHICAGO, NORTH CAROLINA, COLON
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
PSMA,
Investment,
FINANCIAL,
Colorectal cancer,
Neck,
FUTURE,
Renal cell carcinoma,
Head,
EGFR,
Therapy,
Cryptocurrency Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
Key Points:
- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
- FIRST QUARTER 2024 FINANCIAL RESULTS:
Cash and cash equivalents and short-term investments: As of March 31, 2024, Janux reported cash and cash equivalents and short-term investments of $651.8 million compared to $344.0 million at December 31, 2023.
- Research and development expenses: For the quarter ended March 31, 2024, Janux reported research and development expenses of $14.1 million compared to $15.9 million for the comparable period in 2023.
- Net loss: For the quarter ended March 31, 2024, Janux reported a net loss of $14.8 million compared to $17.5 million for the comparable period in 2022.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
NSCLC,
Head,
Cancer,
Incidence,
Neck,
EGFR,
Investment,
Colorectal cancer,
PSMA,
Renal cell carcinoma,
Șaeș,
FINANCIAL,
Therapy,
Liver disease,
Patient,
PSA,
RECIST,
IP,
FUTURE,
CRS,
Infrared spectroscopy correlation table,
Prostate cancer “2023 was a critical year for Janux as we tested the potential power of our TRACTr platform in the clinic.
Key Points:
- “2023 was a critical year for Janux as we tested the potential power of our TRACTr platform in the clinic.
- RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:
Presented positive updated interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer in February 2024.
- Janux plans to deploy these funds to expand development of clinical programs, advance additional preclinical programs and extend corporate runway.
- FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS:
Cash and cash equivalents and short-term investments: As of December 31, 2023, Janux reported cash and cash equivalents and short-term investments of $344.0 million compared to $327.0 million at December 31, 2022.
Retrieved on:
Thursday, February 29, 2024
Biotechnology,
Health,
Pharmaceutical,
Clinical Trials,
Oncology,
Attention,
Lexington Avenue,
Prospectus,
William Blair & Company,
Capital market,
Telephone,
Sale,
Exercise,
Form,
Therapy,
BofA Securities,
Security (finance) The aggregate gross proceeds to Janux from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding the exercise of any pre-funded warrants, are expected to be approximately $296.5 million.
Key Points:
- The aggregate gross proceeds to Janux from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding the exercise of any pre-funded warrants, are expected to be approximately $296.5 million.
- In addition, Janux has granted the underwriters a 30-day option to purchase up to an additional 956,450 shares of its common stock.
- All of the shares to be sold in the offering are to be sold by Janux.
- The offering is expected to close on or about March 4, 2024, subject to customary closing conditions.
Retrieved on:
Tuesday, February 27, 2024
Biotechnology,
Pharmaceutical,
Health,
Oncology,
Attention,
Lexington Avenue,
Prospectus,
William Blair & Company,
Capital market,
Telephone,
Sale,
Form,
Therapy,
BofA Securities,
Security (finance) Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.
Key Points:
- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.
- In addition, Janux expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions.
- All of the shares to be sold in the offering are to be sold by Janux.
- The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Retrieved on:
Monday, February 26, 2024
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Other Science,
Science,
Oncology,
NSCLC,
Head,
Incidence,
Neck,
EGFR,
Toxicity,
TCE,
Colorectal cancer,
SCCHN,
RCC,
Prostate,
PSMA,
Renal cell carcinoma,
CRC,
Lung,
PR,
Glioma,
Interim,
Lung cancer,
Safety,
Breast,
Therapy,
Liver disease,
Patient,
PSA,
RECIST,
Cytokine release syndrome,
CD28,
CRS,
PD-L1,
Cancer “These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors.
Key Points:
- “These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors.
- JANX007 is in a Phase 1a clinical trial in subjects with advanced or metastatic prostate cancer (mCRPC).
- As of February 12, 2024, 23 subjects were treated with JANX007 in the dose escalation portion of the Phase 1a clinical trial.
- Based on this safety profile, we are continuing in the dose escalation and optimization portion of the trial for JANX008.
Retrieved on:
Tuesday, February 20, 2024
Health,
General Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Head,
Neck,
EGFR,
Colorectal cancer,
Prostate,
PSMA,
Renal cell carcinoma,
Lung,
Glioma,
Breast,
Lung cancer,
Safety,
Therapy,
Clinical trial,
CD28,
PD-L1,
Vaccine Specifically, the company will provide clinical efficacy and safety updates to report on progress towards identifying doses for expansion studies with JANX007, and on early dose escalation data for JANX008.
Key Points:
- Specifically, the company will provide clinical efficacy and safety updates to report on progress towards identifying doses for expansion studies with JANX007, and on early dose escalation data for JANX008.
- The company anticipates providing an update on identifying doses to be evaluated in expansion cohorts for JANX007 in 2H 2024.
- Janux’s first clinical candidate, JANX007, is a TRACTr that targets PSMA and is being investigated in a Phase 1 clinical trial in adult subjects with mCRPC.
- In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.
Retrieved on:
Tuesday, February 27, 2024
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Neck,
CD28,
GSK plc,
B.S.E,
Glioma,
PSMA,
Acquisition,
Lung,
Colorectal cancer,
Breast,
EGFR,
Renal cell carcinoma,
Chemical engineering,
Therapy,
Stanford University,
Head,
University,
Prostate,
IP,
Pharmaceutical engineering,
CSO,
PD-L1,
Pharmaceutical industry Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.
Key Points:
- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.
- Before Janux, Tommy was the co-founder of Sitari Pharmaceuticals based upon his graduate work at Stanford University with Professor Chaitan Khosla.
- Tommy was a key leader in the Sitari drug discovery and development program, whose successful culmination was the acquisition by GlaxoSmithKline.
- In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.
Retrieved on:
Tuesday, November 7, 2023
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Other Health,
Colon,
PD-L1,
FUTURE,
FINANCIAL,
CD28,
Renal cell carcinoma,
Colorectal cancer,
Head,
Lung,
Therapy,
Investment,
PSMA,
Breast,
Prostate,
Neck,
Glioma,
EGFR,
Pharmaceutical industry,
Vaccine,
Cryptocurrency Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.
Key Points:
- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2023, and provided a business update.
- Research and development expenses: For the quarter ended September 30, 2023, Janux reported research and development expenses of $11.9 million compared to $13.7 million for the comparable period in 2022.
- Net loss: For the quarter ended September 30, 2023, Janux reported a net loss of $11.6 million compared to $16.7 million for the comparable period in 2022.
- In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Glioma,
FINANCIAL,
CD28,
PSMA,
FUTURE,
Drug,
Head,
Breast,
Prostate,
Neck,
Lung,
Colon,
Investment,
EGFR,
Colorectal cancer,
Therapy,
PD-L1,
Prostate cancer,
Renal cell carcinoma,
Medical imaging,
Cryptocurrency Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the second quarter ended June 30, 2023, and provided a business update.
Key Points:
- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the second quarter ended June 30, 2023, and provided a business update.
- SECOND QUARTER 2023 FINANCIAL HIGHLIGHTS:
Cash and cash equivalents and short-term investments: As of June 30, 2023, Janux reported cash and cash equivalents and short-term investments of $303.3 million compared to $327.0 million at December 31, 2022.
- Net loss: For the quarter ended June 30, 2023, Janux reported a net loss of $17.5 million compared to a net loss of $16.9 million for the comparable period in 2022.
- In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.
